We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$484M
AUM Growth
-$132M
Cap. Flow
-$82.1M
Cap. Flow %
-16.96%
Top 10 Hldgs %
59.62%
Holding
44
New
11
Increased
12
Reduced
4
Closed
16

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$26.7M
2
BIIB icon
Biogen
BIIB
+$20.2M
3
TVTX icon
Travere Therapeutics
TVTX
+$16.4M
4
EXEL icon
Exelixis
EXEL
+$16.4M
5
NVRO
NEVRO CORP.
NVRO
+$13.1M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$45M
2
ZYME icon
Zymeworks
ZYME
+$37.8M
3
VCEL icon
Vericel Corp
VCEL
+$27.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$25.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 94.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
1
MacroGenics
MGNX
$235M
$43M 8.89%
1,350,000
+110,713
+9% +$2.69M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$340M
$33.7M 6.97%
760,000
+60,000
+9% +$3.29M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$1.82B
$29.4M 6.09%
930,000
+12,573
+1% +$521K
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$28.6M 5.91%
382,085
-72,332
-16% -$5.93M
XENT
5
DELISTED
Intersect ENT, Inc
XENT
$27.8M 5.75%
1,332,773
+29,902
+2% +$690K
EXEL icon
6
Exelixis
EXEL
$13.3B
$27.1M 5.61%
1,201,100
+726,100
+153% +$16.4M
UTHR icon
7
United Therapeutics
UTHR
$25.8B
$26.2M 5.41%
156,406
+6,406
+4% +$1.07M
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
$26.1M 5.39%
375,870
+30,750
+9% +$2.37M
PODD icon
9
Insulet
PODD
$11.5B
$23.4M 4.83%
89,600
+29,600
+49% +$7.93M
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.1M 4.78%
+135,000
New +$26.7M
BIIB icon
11
Biogen
BIIB
$30B
$21M 4.34%
+75,000
New +$20.2M
COLL icon
12
Collegium Pharmaceutical
COLL
$1.15B
$20.4M 4.22%
861,410
+440,027
+104% +$10.5M
CNST
13
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$20.4M 4.22%
872,415
-152,385
-15% -$4.62M
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$18.5M 3.82%
4,755,000
+671,091
+16% +$3.07M
OCUL icon
15
Ocular Therapeutix
OCUL
$1.79B
$16.5M 3.42%
1,007,012
+150,850
+18% +$2.91M
TVTX icon
16
Travere Therapeutics
TVTX
$5.2B
$14.8M 3.06%
+593,712
New +$16.4M
LNTH icon
17
Lantheus
LNTH
$6.49B
$13.9M 2.87%
+649,516
New +$11.8M
PBYI icon
18
Puma Biotechnology
PBYI
$404M
$12.6M 2.61%
1,300,000
– –
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$11.2M 2.31%
+80,000
New +$13.1M
IFRX icon
20
InflaRx
IFRX
$250M
$8.58M 1.77%
+2,200,000
New +$11.3M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$4.43B
$8.03M 1.66%
311,217
-409,285
-57% -$18M
LUNG icon
22
Pulmonx
LUNG
$68.8M
$5.23M 1.08%
114,345
+50,000
+78% +$2.87M
RDHL
23
Redhill Biopharma
RDHL
$3.95M
$5.16M 1.07%
+705
New +$5.91M
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$4.57M 0.94%
+250,000
New +$5.16M
YMAB
25
DELISTED
Y-mAbs Therapeutics
YMAB
$4.54M 0.94%
+150,000
New +$6.15M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Great Point Partners held 44 positions worth $484M, down 21% from $616M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners withdrew a net $82.1M in Q1 2021, closing 16 positions and reducing 4 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $45M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Mirati Therapeutics, Inc. Common Stock worth $23.1M.

  • Great Point Partners's largest Q1 2021 buy was Mirati Therapeutics, Inc. Common Stock: 135,000 shares worth $23.1M.
  • Great Point Partners added most to Exelixis in Q1 2021, an estimated $16.4M increase.
  • Great Point Partners's biggest Q1 2021 reduction was Acadia Pharmaceuticals, cutting an estimated $18M.
  • Great Point Partners fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, selling an estimated $45M.
  • Great Point Partners's ten largest holdings make up 60% of its $484M portfolio in Q1 2021.
  • Great Point Partners opened 11 new positions and closed 16 in Q1 2021.
  • Great Point Partners's portfolio value fell 21% quarter-over-quarter to $484M.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.